Future of MedTech: Accelerating the Translation of Regenerative Technologies to Clinical Applications

Regenerative technologies are revolutionizing healthcare by offering new solutions for tissue repair, organ replacement, and functional restoration. The field is rapidly evolving, driven by breakthroughs in bioprinting, novel therapeutic devices, and advances in clinical applications. As these innovations move closer to real-world use, the need to bridge the gap between cutting-edge research and clinical adoption has become increasingly urgent. The integration of regulatory insights, robust engineering tools, and emerging artificial intelligence (AI) methods further accelerates this translation process, maximizing therapeutic impact and supporting global health and innovation goals.

Led by Specialty Chief Editor, Prof. Sarah Cartmell, and Prof. Elmer Ker, this Research Topic aims to highlight advances that accelerate the clinical translation and real-world application of regenerative technologies. By focusing on innovative solutions in bioprinting, therapeutic devices, regulatory strategies, and AI-driven tools, we seek to showcase research and perspectives that overcome barriers to market adoption, support regulatory approval, and ultimately improve patient outcomes.

This Research Topic welcomes submissions around, but not limited to:

• Clinical applications of regenerative technologies
• Advances in bioprinting for multi-material tissue engineering
• Development and assessment of novel therapeutic devices for tissue repair
• Regulatory, policy, and commercialization pathways for regenerative medicine
• Application of AI and machine learning in therapy development, manufacturing, or market adoption
• Quantitative engineering tools or workflows that facilitate translation of regenerative therapies

Manuscripts should emphasize the advancement of regenerative products or methods towards real-world clinical use, highlighting interdisciplinary approaches and contributions to Sustainable Development Goals 3 and 9.